EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced Modulation of CaMKII in Mouse Hippocampus by an Antidepressant-like Dose of Melatonin/Ketamine Combination

Armida Miranda-Riestra iD, Rosa Estrada-Reyes, Luis A Constantino-Jonapa iD, Jesús Argueta, Julián Oikawa-Sala, Miguel A Reséndiz-Gachús iD, Daniel Albarrán-Gaona, Gloria Benítez-King

Cells · 2025

DOI: 10.3390/cells14151187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Armida Miranda-Riestra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Neurofarmacología, Subdirección de Investigaciones Clínicas, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 1…. Hauptthemen laut MEDLINE: Melatonin, Calcium-Calmodulin-Dependent Protein Kinase Type 2, Ketamine, Antidepressive Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Nacional de Humanidades, Ciencias y Tecnologías, CONAHCYT es el Consejo Nacional de Humanidades, Ciencias y Tecnologías.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Forty per cent of major depression patients are resistant to antidepressant medication. Thus, it is necessary to search for alternative treatments. Melatonin (N-acetyl-5-hydroxytryptamine) enhances neurogenesis and neuronal survival in the adult mouse hippocampal dentate gyrus. Additionally, melatonin stimulates the activity of Ca2+/Calmodulin-dependent Kinase II (CaMKII), promoting dendrite formation and neurogenic processes in human olfactory neuronal precursors and rat organotypic cultures. Similarly, ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, modulates CaMKII activity. Importantly, co-treatment of low doses of ketamine (10−7 M) in combination with melatonin (10−7 M) produces additive effects on neurogenic responses in olfactory neuronal precursors. Importantly, enhanced neurogenic responses are produced by conventional antidepressants like ISSRs. The goal of this study was to investigate whether hippocampal CaMKII participates in the signaling pathway elicited by combining doses of melatonin with ketamine acutely administered to mice, 30 min before being subjected to the forced swimming test. The results showed that melatonin, in conjunction with ketamine, significantly enhances CaMKII activation and changes its subcellular distribution in the dentate gyrus of the hippocampus. Remarkably, melatonin causes nuclear translocation of the active form of CaMKII. Luzindole, a non-selective MT1 and MT2 receptor antagonist, abolished these effects, suggesting that CaMKII is downstream of the melatonin receptor pathway that causes the antidepressant-like effects. These findings provide molecular insights into the combined effects of melatonin and ketamine on neuronal plasticity-related signaling pathways and pave the way for combating depression using combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelatoninCalcium-Calmodulin-Dependent Protein Kinase Type 2KetamineAntidepressive AgentsHippocampusAnimalsMiceMaleMice, Inbred C57BLNeurogenesisDentate GyrusSignal Transduction

Stichwörter der Autor:innen

CaMKIIketaminemayor depressionmelatoninmelatonin receptors

Substanzen

MelatoninCalcium-Calmodulin-Dependent Protein Kinase Type 2KetamineAntidepressive Agents

Autor:innen und Institutionen

  • Laboratorio de Neurofarmacología, Subdirección de Investigaciones Clínicas, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico.
  • Laboratorio de Fitofarmacología, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico.

ORCID-Profile: Armida Miranda-Riestra, Luis A Constantino-Jonapa, Miguel A Reséndiz-Gachús

Förderung

  • Consejo Nacional de Humanidades, Ciencias y Tecnologías
  • CONAHCYT es el Consejo Nacional de Humanidades, Ciencias y Tecnologías

Zitieren

APA

Miranda-Riestra, A., Estrada-Reyes, R., Constantino-Jonapa, L. A., Argueta, J., Oikawa-Sala, J., Reséndiz-Gachús, M. A., Albarrán-Gaona, D., & Benítez-King, G. (2025). Enhanced Modulation of CaMKII in Mouse Hippocampus by an Antidepressant-like Dose of Melatonin/Ketamine Combination. Cells. https://doi.org/10.3390/cells14151187

Vancouver

Miranda-Riestra A, Estrada-Reyes R, Constantino-Jonapa LA, Argueta J, Oikawa-Sala J, Reséndiz-Gachús MA, et al. Enhanced Modulation of CaMKII in Mouse Hippocampus by an Antidepressant-like Dose of Melatonin/Ketamine Combination. Cells. 2025. doi:10.3390/cells14151187

BibTeX
@article{MirandaRiestra2025,
  author = {Miranda-Riestra, Armida and Estrada-Reyes, Rosa and Constantino-Jonapa, Luis A and Argueta, Jesús and Oikawa-Sala, Julián and Reséndiz-Gachús, Miguel A and Albarrán-Gaona, Daniel and Benítez-King, Gloria},
  title = {Enhanced Modulation of CaMKII in Mouse Hippocampus by an Antidepressant-like Dose of Melatonin/Ketamine Combination},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14151187}
}
Kostenlos starten →